1 / 8

Blood Cancer Drugs Market Trends, Size, Growth and Forecast to 2025

The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period.

priyankauke2013
Download Presentation

Blood Cancer Drugs Market Trends, Size, Growth and Forecast to 2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Blood Cancer Drugs Market Market Size Worth $55.6 Billion by 2025 | CAGR: 11.1%

  2. Blood Cancer Drugs Market Size Worth $55.6 Billion by 2025 “According to Polaris Market Research report, Blood Cancer Drugs is one of the rapidly evolving industry and the global Blood Cancer Drugs Market is estimated to reach $55.6 Billion by 2025 registering a healthy CAGR of 11.1% over the forecast period 2017 to 2025” The global Blood Cancer Drugs Market is driven by certain key factors such as technological innovation in the Blood Cancer Drugs industry, favorable regulatory scenario encouraging market players to develop new products, and efforts by manufacturers to boost the adoption of their offerings. Additionally, industry players are working on business expansion to target untapped markets and managing to deliver their products & services worldwide to augment their revenues. Blood Cancer Drugs Market Report Scope: The research report covers the segmentation of the Blood Cancer Drugs Market based on Blood Cancer Type, Drugs, Treatment Approaches and region. Analysis of each of the segments projects the snapshot of the market over the forecast years includes the inclination of the market revenue, prevailing patterns, and emerging trends. Increasing consumer awareness regarding products coupled with a rise in disposable income is projected to propel the growth of the Blood Cancer Drugs Market over the forecast period. - 2 -

  3. Blood Cancer Drugs Market Size Worth $55.6 Billion by 2025 By Blood Cancer By Drugs By Treatment Approaches By Region Type •Lymphoma •Leukemia •Myeloma •Rituaxan/Mabthera (Rituximab) •Gleevac/Glivec (Imatinib) •Revlimid (Lenalidomide) •Velcade (Bortezomib) •Tasigna (Nilotinib) •Pomalyst (Pomalidomide) •Vidaza (Azacitidine) •Kyprolis (Carfilzomib) •Adcetris (Brentuximab Vedotin) •Others •Chemotherapeutic •North America (U.S., Canada) •mAbs/Targeted Therapies •Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria) •Immunotherapeutic •Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) •Latin America (Brazil, Mexico, Argentina) •Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa) Browse Detailed Research Report On Blood Cancer Drugs Market Analysis: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market Regional Outlook North America is anticipated to witness a significant growth rate with major revenue contribution in the Blood Cancer Drugs Market during the forecast period. Major factors influencing the regional market growth include improved infrastructural facilities, positive government initiatives, and the presence of established market players. The Blood Cancer Drugs Market in the Asia Pacific region is projected to grow at a substantial rate over the forecast period. The regional growth is attributed to increasing investments by leading companies to bring innovation in Blood Cancer Drugs industry and attract a large consumer base from leading economies such as India and China. Gain access to our latest research report that includes a detailed analysis of the COVID-19 pandemic influencing the Blood Cancer Drugs market and how market players devising effective strategies to mitigate the effect of the pandemic: - 3 -

  4. Blood Cancer Drugs Market Size Worth $55.6 Billion by 2025 https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/speak-to- analyst Competitive Landscape According to Polaris Market Research, the key players with a considerable market share in the Blood Cancer Drugs Market include (Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc., Roche Holding AG, Celgene Corporation, Merck and Company, Novartis AG, and GlaxoSmithKline Pharmaceuticals Ltd. among others). Companies are focusing on R&D activities and strategic collaborations to improve their product portfolio and increase consumer base. Adoption of the latest technologies and product advancement is the key strategy adopted by leading market players. Request for sample: https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer- drugs-market/request-for-sample Table of Contents 1.Overview and Scope 1.1.Research goal & scope 1.2.Research assumptions 1.3.Research methodology 1.3.1.Primary data sources 1.3.2.Secondary data sources 1.4.Key take-away 1.5.Stakeholders 2.Executive Summary 2.1.Market definition 2.2.Market segmentation 3.Blood cancer drugs market Insights 3.1.Blood Cancer Drug – Industry snapshot 3.1.1.Leading Companies 3.1.2.Emerging Companies & Technologies Platform 3.1.3.Key Companies to Watch 3.2.Blood Cancer Drug - Ecosystem analysis 3.2.1.Disease overview 3.2.2.Commercial Landscape 3.2.3.Future Treatment Paradigm 3.3.Blood cancer drugs market Dynamics 3.3.1.Blood Cancer Drug – Market Forces 3.3.1.1. Blood cancer drugs market Driver Analysis 3.3.1.2. Blood cancer drugs market Restraint/Challenges analysis 3.3.1.3. Blood Cancer Market Opportunity Analysis 3.3.2.Industry analysis - Porter's five forces 3.3.2.1. Bargaining power of supplier 3.3.2.2. Bargaining power of buyer 3.3.2.3. Threat of substitute - 4 -

  5. Blood Cancer Drugs Market Size Worth $55.6 Billion by 2025 3.3.2.4. 3.3.2.5. 3.3.3.Blood cancer drugs market PEST Analysis, 2017 3.3.4.Blood cancer drugs market Value Chain Analysis 3.3.5.Blood Cancer Drug Industry Trends 3.3.6.Competitive Ranking Analysis 4.Blood cancer drugs market Size and Forecast, 2017-2025 by Blood Cancer Type 4.1.Key Findings 4.2.Lymphoma 4.2.1.Hodgkin Lymphoma 4.2.2.Non-Hodgkin Lymphoma 4.2.2.1. B-cell Lymphoma 4.2.2.1.1. Diffuse Large B-Cell Lymphoma 4.2.2.1.2. Mantle Cell Lymphoma 4.2.2.1.3. Burkitt Lymphoma 4.2.2.1.4. Central Nervous System Lymphoma 4.2.2.2. T-cell Lymphoma 4.2.2.2.1. Precursor T-Lymphoblastic Lymphoma 4.2.2.2.2. Peripheral T-Lymphoma 4.2.3. Leukemia 4.2.3.1. Acute Myeloid Leukemia 4.2.3.2. Chronic Myeloid Leukemia 4.2.3.3. Acute Lymphoblastic Leukemia 4.2.3.4. Chronic Lymphocytic Leukemia 4.2.4.Myeloma 4.2.4.1. Multiple Myeloma 5.Blood cancer drugs market Size and Forecast, 2017-2025 by Drugs 5.1.Rituaxan/Mabthera (Rituximab) 5.2.Gleevac/Glivec (Imatinib) 5.3.Revlimid (Lenalidomide) 5.4.Velcade (Bortezomib) 5.5.Tasigna (Nilotinib) 5.6.Pomalyst (Pomalidomide) 5.7.Vidaza (Azacitidine) 5.8.Kyprolis (Carfilzomib) 5.9.Adcetris (Brentuximab Vedotin) 5.10. Others 6.Blood cancer drugs market Size and Forecast, 2017-2025 by Treatment Approaches 6.1.Key Findings 6.2.Chemotherapeutic 6.3.mAbs/Targeted Therapies 6.4.Immunotherapeutic 7.Blood cancer drugs market Size and Forecast, 2017-2025 by Region 7.1.Key Findings 7.2.North America 7.2.1.Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.2.2.Blood Cancer Drugs Market by drugs, 2017 – 2025 7.2.3.Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.2.4.U.S. 7.2.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.2.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 Threat of new entrant Degree of competition - 5 -

  6. Blood Cancer Drugs Market Size Worth $55.6 Billion by 2025 7.2.4.3. 7.2.5.Canada 7.2.5.1. 7.2.5.2. 7.2.5.3. 7.3.Europe 7.3.1.Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.3.2.Blood Cancer Drugs Market by drugs, 2017 – 2025 7.3.3.Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.3.4.UK 7.3.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.3.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.3.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.3.5.Germany 7.3.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.3.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.3.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.3.6.France 7.3.6.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.3.6.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.3.6.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.4.Asia-Pacific 7.4.1.Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.4.2.Blood Cancer Drugs Market by drugs, 2017 – 2025 7.4.3.Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.4.4.China 7.4.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.4.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.4.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.4.5.Japan 7.4.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.4.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.4.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.4.6.India 7.4.6.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.4.6.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.4.6.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.5.Latin America 7.5.1.Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.5.2.Blood Cancer Drugs Market by drugs, 2017 – 2025 7.5.3.Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.5.4.Brazil 7.5.4.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.5.4.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.5.4.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.5.5.Mexico 7.5.5.1. Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 7.5.5.2. Blood Cancer Drugs Market by drugs, 2017 – 2025 7.5.5.3. Blood Cancer Drugs Market by treatment approach, 2017 – 2025 7.6.Middle East & Africa 7.6.1.Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 Blood Cancer Drugs Market by treatment approach, 2017 – 2025 Blood Cancer Drugs Market by blood cancer type, 2017 – 2025 Blood Cancer Drugs Market by drugs, 2017 – 2025 Blood Cancer Drugs Market by treatment approach, 2017 – 2025 - 6 -

  7. Blood Cancer Drugs Market Size Worth $55.6 Billion by 2025 7.6.2.Blood Cancer Drugs Market by drugs, 2017 – 2025 7.6.3.Blood Cancer Drugs Market by treatment approach, 2017 – 2025 8.Company Profiles 8.1.Johnson & Johnson Inc. 8.1.1.Overview 8.1.2.Financials 8.1.3.Product Benchmarking 8.1.4.Recent Developments 8.2.Amgen Inc. 8.2.1.Overview 8.2.2.Financials 8.2.3.Product Benchmarking 8.2.4.Recent Developments 8.3.Bayer AG. 8.3.1.Overview 8.3.2.Financials 8.3.3.Product Benchmarking 8.3.4.Recent Developments 8.4.Pfizer Inc. 8.4.1.Overview 8.4.2.Financials 8.4.3.Product Benchmarking 8.4.4.Recent Developments 8.5.Eli Lily & Co. 8.5.1.Overview 8.5.2.Financials 8.5.3.Product Benchmarking 8.5.4.Recent Developments 8.6.AstraZeneca 8.6.1.Overview 8.6.2.Financials 8.6.3.Product Benchmarking 8.6.4.Recent Developments 8.7.AbbVie Inc. 8.7.1.Overview 8.7.2.Financials 8.7.3.Product Benchmarking 8.7.4.Recent Developments 8.8.Roche Holding AG 8.8.1.Overview 8.8.2.Financials 8.8.3.Product Benchmarking 8.8.4.Recent Developments 8.9.Celgene Corporation. 8.9.1.Overview 8.9.2.Financials 8.9.3.Product Benchmarking 8.9.4.Recent Developments 8.10. Merck and Company 8.10.1.Overview 8.10.2.Financials - 7 -

  8. Blood Cancer Drugs Market Size Worth $55.6 Billion by 2025 8.10.3.Product Benchmarking 8.10.4.Recent Developments 8.11. Novartis AG. 8.11.1.Overview 8.11.2.Financials 8.11.3.Product Benchmarking 8.11.4.Recent Developments 8.12. GlaxoSmithKline Pharmaceuticals Ltd. 8.12.1.Overview 8.12.2.Financials 8.12.3.Product Benchmarking 8.12.4.Recent Developments Access Press Release on Blood Cancer Drugs Market: https://www.polarismarketresearch.com/press- releases/global-blood-cancer-drugs-market About Polaris Market Research Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers. E mail Id: sales@polarismarketresearch.com Web: www.polarismarketresearch.com Official Blog: http://polarismarketresearch.blogspot.com - 8 -

More Related